Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell therapy in Parkinson's disease.

Olle Lindvall1, Anders Björklund

  • 1Wallenberg Neuroscience Center and Lund Strategic Center for Stem Cell Biology and Cell Therapy, BMC A11, SE-221 84 Lund, Sweden. olle.lindvall@neurol.lu.se

Neurorx : the Journal of the American Society for Experimental Neurotherapeutics
|February 18, 2005
PubMed
Summary

Intrastriatal fetal cell transplants offer Parkinson's disease (PD) proof-of-principle but face challenges. Future cell therapies require standardized neuron production and optimized transplantation strategies for improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson's disease.

BMJ open·2025
Same author

Human cortical neurons rapidly generated by embryonic stem cell programming integrate into the stroke-injured rat cortex.

Stem cells (Dayton, Ohio)·2025
Same author

The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.

Nature biotechnology·2025
Same author

TARGET-seq: Linking single-cell transcriptomics of human dopaminergic neurons with their target specificity.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

History of cellular grafting for central nervous system repair-A clinical perspective.

Handbook of clinical neurology·2024
Same author

The history and status of dopamine cell therapies for Parkinson's disease.

BioEssays : news and reviews in molecular, cellular and developmental biology·2024

Area of Science:

  • Neuroscience
  • Cell Biology
  • Regenerative Medicine

Background:

  • Clinical studies using fetal mesencephalic tissue transplants in Parkinson's disease (PD) patients demonstrate proof-of-principle for cell replacement therapy.
  • Grafted dopaminergic neurons can reinnervate the striatum, restore dopamine release, and improve motor function, leading to significant symptomatic relief in some patients.
  • Successful cases show patients withdrawing L-dopa medication and regaining independence, highlighting the potential of this therapeutic approach.

Purpose of the Study:

  • To review the current status and challenges of cell replacement therapy for Parkinson's disease.
  • To identify key areas for future research and development to advance cell-based therapies for PD.
  • To discuss the potential of stem cell technology in generating dopaminergic neurons for PD treatment.

Related Experiment Videos

Main Methods:

  • Review of clinical studies on intrastriatal fetal tissue transplantation in Parkinson's disease patients.
  • Analysis of the benefits and limitations of current cell replacement strategies.
  • Exploration of future research directions, including stem cell technology.

Main Results:

  • Fetal cell transplantation can lead to significant symptomatic relief and functional improvement in PD patients.
  • Challenges include limited tissue availability, variable patient outcomes, and the occurrence of dyskinesias.
  • Stem cell technology offers a potential solution for generating a consistent supply of dopaminergic neurons.

Conclusions:

  • Neural transplantation for Parkinson's disease is still experimental, requiring better patient selection and graft optimization.
  • Further research is needed on graft composition, immunological factors, and preventing dyskinesias.
  • Stem cell-derived dopaminergic neurons hold promise but require further scientific validation before clinical application in PD.